Concurrency | Jotup

Surge Copper Announces C$3.8 Million Strategic Investment by African Rainbow Minerals Limited

Retrieved on:

Tuesday, April 2, 2024

Copper, IRA, National Instrument 43-101, TSX Venture Exchange, SURG, South African Reserve Bank, News, ARM, Acquisition, National instrument, TSX, Concurrency, Strategy, ARI, Qualified person (European Union), Security (finance)

Vancouver, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- Surge Copper Corp. (TSXV: SURG ) (OTCQB: SRGXF ) (Frankfurt: G6D2 ) (“Surge” or the “Company”) is pleased to announce that it has entered into a subscription agreement for a private placement financing (the “Strategic Placement”) with a new cornerstone strategic investor, African Rainbow Minerals Limited (JSE: ARI) (“ARM”).

Key Points:

Vancouver, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- Surge Copper Corp. (TSXV: SURG ) (OTCQB: SRGXF ) (Frankfurt: G6D2 ) (“Surge” or the “Company”) is pleased to announce that it has entered into a subscription agreement for a private placement financing (the “Strategic Placement”) with a new cornerstone strategic investor, African Rainbow Minerals Limited (JSE: ARI) (“ARM”).
Under the terms of the Strategic Placement, ARM, through its wholly-owned subsidiary ARM Copper Company Proprietary Limited (“ARM Copper”), will subscribe for 39,608,708 common shares (the “Strategic Placement Common Shares”) of Surge at C$0.095 per Strategic Placement Common Share, representing an approximately 18% premium to the 20-day volume weighted average price of the Company’s common shares on the TSX Venture Exchange as at April 1, 2024, for gross proceeds of approximately C$3,762,827.
Upon completion of the Strategic Placement, ARM (through ARM Copper) will own 15.0% of Surge’s issued and outstanding common shares on a non-diluted basis.
Leif Nilsson, Chief Executive Officer, commented: “We are excited to be welcoming ARM as a strategic investor into Surge.

Power Leaves Corp. Enters Into LOI for RTO; Targets Public Listing in H1 2024

Retrieved on:

Wednesday, March 27, 2024

Completion, Growth, Exchange, PLC, Cboe Global Markets, LOI, Concurrency, Issuer, Security (finance)

TORONTO, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Power Leaves Corp. (“PLC”), a manufacturer and international distributor of decocainized coca leaf derivatives, is pleased to announce that it has entered into a non-binding letter of intent (the "LOI") with Rockshield Acquisition Corp. ("Rockshield"). The LOI outlines key terms under which Rockshield will acquire all of the issued and outstanding securities of PLC through a reverse takeover transaction (the “Proposed Transaction”).

Key Points:

The LOI outlines key terms under which Rockshield will acquire all of the issued and outstanding securities of PLC through a reverse takeover transaction (the “Proposed Transaction”).
In connection with the Proposed Transaction, the Resulting Issuer will apply to list its common shares on Cboe Canada (the “Exchange”) by way of a direct listing.
The Proposed Transaction is subject to the parties successfully entering into a definitive agreement (the “Definitive Agreement”) in respect of the Proposed Transaction.
The Closing is expected to occur before the end of June 2024.

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy

Retrieved on:

Monday, March 25, 2024

AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo.

Key Points:

AXS-12 also reduced excessive daytime sleepiness (EDS) severity, improved cognitive function, and reduced overall narcolepsy severity as compared to placebo.
SYMPHONY was a Phase 3 multicenter, randomized, double-blind, placebo-controlled trial in which 90 patients with a diagnosis of narcolepsy with cataplexy were randomized to treatment with AXS-12 or placebo for 5 weeks.
“The SYMPHONY Phase 3 trial results confirm the promise and potential of AXS-12 for the treatment of narcolepsy,” said Dr. Herriot Tabuteau, CEO of Axsome Therapeutics.
Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss the topline SYMPHONY study results in narcolepsy.

Titan Announces Merger Agreement with Conavi

Retrieved on:

Monday, March 18, 2024

TSX Venture Exchange, Agreement, Health Canada, IP, OCT, RAS, Chairperson, Toronto Stock Exchange, Consolidation, Combined, Reverse, Concurrency, Food, TMD, TSX, Transaction, IVUS, Security (finance)

TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction.

Key Points:

TORONTO, Ontario, March 18, 2024 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies in an all-stock transaction.
Under the terms of the Agreement, Titan will acquire all of the issued and outstanding shares of Conavi (the “Conavi Shares”) and in exchange Conavi shareholders will be issued common shares of Titan (the “Combined Entity Shares”).
Throughout 2023, it was made clear to Titan that a merger with another RAS company was not a viable option and Titan broadened its search for a merger partner beyond RAS.
The Titan Board is unanimous in its decision to execute the Amalgamation Agreement and to recommend this Transaction to its shareholders (the “Titan Shareholders”).

MegaWatt Announces Closing of Final Tranche of Concurrent Private Placement of Shares and Engagement of Outside The Box Capital for Marketing Services

Retrieved on:

Friday, March 15, 2024

Lithium, Tax, Sale, News, PP, Concurrency, Marketing, Legislation, CAD, Watt, Person

All securities issued in connection with the Concurrent PP are subject to a statutory hold period of four months plus a day in accordance with applicable securities legislation ending on July 16, 2024.

Key Points:

All securities issued in connection with the Concurrent PP are subject to a statutory hold period of four months plus a day in accordance with applicable securities legislation ending on July 16, 2024.
In connection with the Concurrent PP, the Company has paid an eligible finder a cash commission in the aggregate amount of $3,850.
The Company will use the net proceeds from the Concurrent PP for property payments, property exploration and for general working capital.
In addition to the closing of the Concurrent PP, the Company is also pleased to announce that it has entered into a marketing services agreement (the “Marketing Agreement”) with an arm’s length firm, Outside The Box Capital Inc. (“OTBC”) of Oakville, Ontario, to provide, among other things, marketing and distribution services to communicate to the financial community information about the Company.

Concurrent Continues to Hit Growth Projections, Adds Three New Advisors at the start of 2024

Retrieved on:

Wednesday, March 13, 2024

Consulting, Asset Management, Professional Services, Finance, Wells Fargo, Marketing, Growth, Concurrency, Financial adviser

Concurrent Investment Advisors , LLC (“Concurrent”), a leading multi-custodial, hybrid registered investment adviser (“RIA”), continues to meet its growth projections, attracting three new advisors to its platform from Wells Fargo and Raymond James.

Key Points:

Concurrent Investment Advisors , LLC (“Concurrent”), a leading multi-custodial, hybrid registered investment adviser (“RIA”), continues to meet its growth projections, attracting three new advisors to its platform from Wells Fargo and Raymond James.
Ramin Abrams and Glenn Holmes aligned with Concurrent to position their firms for continued growth while tapping into the platform’s multi-custodial offerings, modern technology, and operational support team.
In addition to building their flagship businesses under Concurrent’s wing, advisors can also join existing Concurrent partner firms.
Sean O’Neill has joined Legacy Wealth Partners, a Denver-based firm already well established in the Concurrent network.

Projetech Commits to the Latest Version of IBM Maximo Application Suite for Internal and Client Upgrades, Demonstrating Unwavering Confidence in the Platform

Retrieved on:

Monday, March 11, 2024

Trust, Red, Gentlemen's agreement, IBM, Kubernetes, OCP, Concurrency, SLA, MAS, Self-service, Asset management

CINCINNATI, March 11, 2024 /PRNewswire-PRWeb/ -- Projetech, a trailblazer in enterprise asset management, has announced its strategic move to adopt IBM Maximo Application Suite's latest version for its internal operations and forthcoming client upgrades. This decision showcases Projetech's trust in the platform's capabilities and commitment to staying at the forefront of technological innovation in asset management.

Key Points:

Projetech, a trailblazer in enterprise asset management, has announced its strategic move to adopt IBM Maximo Application Suite's latest version for both its internal operations and forthcoming client upgrades.
CINCINNATI, March 11, 2024 /PRNewswire-PRWeb/ -- Projetech, a trailblazer in enterprise asset management, has announced its strategic move to adopt IBM Maximo Application Suite's latest version for its internal operations and forthcoming client upgrades.
This decision showcases Projetech's trust in the platform's capabilities and commitment to staying at the forefront of technological innovation in asset management.
Any organization considering an upgrade to Maximo Application Suite can confidently proceed with Projetech, assured of receiving expert guidance and support throughout the transition process.

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on:

Thursday, March 7, 2024

GAITHERSBURG, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today reported financial results for the full year ended December 31, 2023, and recent corporate updates.

Key Points:

Enrollment remains ongoing in the Company’s Phase 2b randomized, double-blind, placebo-controlled trial of Descartes-08 in patients with MG (NCT04146051), with topline results expected in mid-2024.
Announced Positive Long-Term Follow-Up Data from Phase 2a Study of Descartes-08 in Patients with MG.
In January 2024, Cartesian announced that the FDA cleared its IND application for Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T product candidate.
General and administrative expenses were $40.6 million for the year ended December 31, 2023, compared to $23.9 million for the year ended December 31, 2022.

Rogers Sugar Announces a $110 Million Equity Offering to Fund a Portion of its Sugar Capacity Expansion Project

Retrieved on:

Monday, February 26, 2024

Greater Toronto Area, Investment, BMO Capital Markets, Rogers Sugar, TSX, Toronto Stock Exchange, Growth, Sale, Exercise, Concurrency, Private, Indian stock exchange, Equity, Expansion, Underwriting, RSI, Public, Security (finance)

The sale of Common Shares is pursuant to a bought deal public offering (the “Public Offering”) and two concurrent non-brokered private placements (the “Concurrent Private Placements” and, collectively with the Public Offering, the “Equity Offerings”).

Key Points:

The sale of Common Shares is pursuant to a bought deal public offering (the “Public Offering”) and two concurrent non-brokered private placements (the “Concurrent Private Placements” and, collectively with the Public Offering, the “Equity Offerings”).
In addition, longtime Rogers Sugar shareholder Belkorp Industries Inc. (“Belkorp”) has agreed to purchase approximately $10 million of Common Shares, also by way of a concurrent private placement.
The Expansion Project will increase the production capacity of Lantic’s Montreal plant by approximately 20%, or 100,000 metric tonnes.
The total investment for the Expansion Project is estimated at approximately $200 million.

Independent Proxy Advisory Firm Glass Lewis Recommends Latitude Uranium Shareholders Vote FOR the Arrangement Resolution with ATHA Energy

Retrieved on:

Tuesday, February 20, 2024

OTCQB, Uranium, Meeting, FRA, ISS, LUR, Concurrency, Holding company

TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Latitude Uranium Inc. (“Latitude Uranium”, “LUR” or the “Company”) (CSE: LUR, OTCQB: LURAF, FRA: EI1) is pleased to announce that Glass Lewis & Co. (“Glass Lewis”), an independent proxy advisory firm, has recommended that Latitude Uranium shareholders (“Shareholders”) vote “FOR” the resolution (the "Arrangement Resolution”) to approve the previously announced arrangement (the “Arrangement”) involving the Company and ATHA Energy Corp. (“ATHA”) at the upcoming Special Meeting of Shareholders (the “Meeting”) to be held on Tuesday, February 27, 2024 at 10:00 a.m. (Toronto time).

Key Points:

• The Board of Directors of LUR unanimously recommends that Shareholders vote FOR the Arrangement Resolution.
TORONTO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Latitude Uranium Inc. (“Latitude Uranium”, “LUR” or the “Company”) (CSE: LUR, OTCQB: LURAF, FRA: EI1) is pleased to announce that Glass Lewis & Co. (“Glass Lewis”), an independent proxy advisory firm, has recommended that Latitude Uranium shareholders (“Shareholders”) vote “FOR” the resolution (the "Arrangement Resolution”) to approve the previously announced arrangement (the “Arrangement”) involving the Company and ATHA Energy Corp. (“ATHA”) at the upcoming Special Meeting of Shareholders (the “Meeting”) to be held on Tuesday, February 27, 2024 at 10:00 a.m. (Toronto time).
John Jentz, Chief Executive Officer of Latitude Uranium, commented, “Having recently received a positive recommendation from ISS, we are pleased that Glass Lewis also supports the Board’s unanimous recommendation that shareholders vote “FOR” the Arrangement Resolution.
If you have questions about the Meeting matters or require voting assistance please contact Latitude Uranium‘s proxy solicitation agent, Laurel Hill Advisory Group at: